Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nesvategrast
- Development stage
- Phase 2
- Lead developer
- OcuTerra Therapeutics
- Modality
- Small Molecules
- Administration
- Topical, Ophthalmic
01
Overview
Nesvategrast is a small molecule drug that acts as an integrin αvβ3, αvβ6, and αvβ8 antagonist. It is being developed by OcuTerra Therapeutics for the treatment of diabetic retinopathy. The drug is administered topically as eye drops and has shown safety and tolerability in clinical trials, though it failed to meet primary efficacy endpoints in a Phase II trial for diabetic retinopathy.
- Other names
- SF0166 free acidSF-0166 free acidSF 0166 free acidUNII-49958O183ZUNII49958O183ZUNII 49958O183Z1621332-91-9
02
Targets
αVβ3 (Integrin αVβ3)αVβ6 (Integrin αVβ6)αVβ8 (Integrin alpha V beta 8)
Beyond the preview
Go deeper on nesvategrast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nesvategrast.